2nd GLP-1-Based Therapeutics Summit 2025

It is no secret that GLP-1 receptor agonists have transformed the treatment of obesity and diabetes. The past 12 months have seen the GLP-1 landscape transform into something truly unrecognizable in previous years, with the global GLP-1 analogues market valued at US$47.4 billion in 2024.

With the next frontier of these blockbuster therapeutics well on its way to approval, the GLP-1 field is only going to grow, with novel combinations, indications, and formulations being explored. From MASH to Parkinson's disease, there is potential for GLP-1s to become a ‘magic bullet' across healthcare, only adding to the ever-increasing market value.

In this highly competitive market, Novo Nordisk and Eli Lilly currently lead with first-in-class GLP-1 therapies. However, the race is now focused on developing 'best-in-class' therapies that offer superior efficacy, particularly in weight loss, and are delivered through more convenient formats.

Despite significant progress, challenges remain. From oral formulations to agonist combinations, from muscle preservation to indication expansion, the question remains: who will be the next company to bring a GLP-1-based therapeutic to the market?

The 2nd GLP-1-Based Therapeutics Summit is your dedicated platform for leaders and decision-makers to connect, collaborate, and continue to transform healthcare as we know it through the development of GLP-1s.

 

Prices:
Drug Developer Pricing* - Conference + 2 Workshops : USD 4197.00,
Drug Developer Pricing* - Conference + 1 Workshop: USD 3598.00,
Drug Developer Pricing* - Conference Only: USD 2999.00,
Academic Pricing** - Conference + 2 Workshops: USD 3597.00,
Academic Pricing** - Conference + 1 Workshop Only: USD 3098.00,
Academic Pricing** - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4398.00,
Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Adam Bell, Vice President, Translational Medicine and Regulatory Affairs, Neuraly, Andrew Young, Chief Scientific and Medical Officer, I2O Therapeutics, Belle van Rosmalen, Director - Incretin Outcomes, Eli Lilly and Co., Damian Bialonczyk, Global Medical Lead - Metabolism, Roche, David Glass, Vice President - Research, Regeneron, Elisa Araldi, Professor, University of Parma, Hong Chen, Director - Search and Evaluation, Novo Nordisk, Jason Mastaitis, Sr. Principal Scientist, Regeneron, Jay Caplan, President and Founder, Fractyl Health, Jerry Colca, Chief Scientific Officer, Cirius Therapeutics, Johan Fredrik Paulsson, Director – Incretin and Amylin Biology, Novo Nordisk, Mina Sooch, Founder and General Partner, Apjohn Ventures, Scott Harris, Chief Medical Officer, Altimmune, Zohar Barbash, Chief Technology Officer, Lembas Bio

Others Details

Brochure: https://go.evvnt.com/2858244-3?pid=6581